Robotic surgery in ovarian cancer
- PMID: 37573801
- DOI: 10.1016/j.bpobgyn.2023.102391
Robotic surgery in ovarian cancer
Erratum in
-
Corrigendum to "Robotic surgery in ovarian cancer" [Best Pract Res Clin Obst Gynaecol Volume 90 (August 2023) 102391].Best Pract Res Clin Obstet Gynaecol. 2023 Dec;91:102419. doi: 10.1016/j.bpobgyn.2023.102419. Epub 2023 Sep 14. Best Pract Res Clin Obstet Gynaecol. 2023. PMID: 37717301 No abstract available.
Abstract
Ovarian cancer (OC) represents one of the most lethal cancers in women. The aim of surgical treatment is complete cytoreduction in advanced stages and a surgical staging in early stages. Although the guidelines still suggest laparotomy as the standard approach, in recent years minimally invasive surgery (MIS) has become increasingly popular in the treatment of OC, especially in early stages, because the 5-year relative survival exceeds 90% and the patients' quality of life cannot be overshadowed. However, MIS has been demonstrated to have a role even in advanced stages, in the prediction of optimal cytoreduction, identification patients who may benefit from neoadjuvant chemotherapy, and, more recently, in the interval debulking surgery, as in selected cases of secondary cytoreduction for recurrent ovarian cancer. The aim of this review is to describe the MIS (especially robotic surgery), with its advantages and pitfalls, in the treatment of OC.
Keywords: Minimally invasive surgery; Ovarian cancer; Robotic surgery.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest None.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources